mianserin has been researched along with Alcohol Drinking in 5 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mianserin treatment significantly attenuated ethanol intake and antagonized the voluntary ethanol-induced reduction in expression of CaM kinase IV and CREB phosphorylation in the shell of NAc." | 1.31 | Effects of voluntary ethanol intake on the expression of Ca(2+) /calmodulin-dependent protein kinase IV and on CREB expression and phosphorylation in the rat nucleus accumbens. ( Misra, K; Pandey, SC; Roy, A, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Bejczy, A | 1 |
| Söderpalm, B | 1 |
| Brunette, MF | 1 |
| Akerman, SC | 1 |
| Dawson, R | 1 |
| O'Keefe, CD | 1 |
| Green, AI | 1 |
| Cornelius, JR | 1 |
| Chung, T | 1 |
| Douaihy, AB | 1 |
| Kirisci, L | 1 |
| Glance, J | 1 |
| Kmiec, J | 1 |
| FitzGerald, D | 1 |
| Wesesky, MA | 1 |
| Salloum, I | 1 |
| Misra, K | 1 |
| Roy, A | 2 |
| Pandey, SC | 2 |
| Mittal, N | 1 |
| Zhang, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.[NCT02185131] | Phase 2 | 16 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial[NCT02646449] | Phase 2 | 11 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Level of drinking, as indicated by the number of drinks per day as recorded on the Timeline Follow-Back calendar. (NCT02185131)
Timeframe: 12 Weeks
| Intervention | Drinks per drinking day (Mean) |
|---|---|
| Mirtazapine | 3.5 |
| Placebo | 4.4 |
Level of depressive symptoms, as indicated by the score on the Beck Depression Inventory. The Beck Depression Inventory II scoring range is as follows: 0-13 minimal depressive symptoms, 14-19 mild depressive symptoms, 20-28 moderate depressive symptoms and 29-63 severe depressive symptoms. (NCT02185131)
Timeframe: 12 Weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| Mirtazapine | 27.6 |
| Placebo | 26.1 |
Level of drinking, as indicated by the number of drinks per day as recorded on the Timeline Follow-Back calendar. (NCT02646449)
Timeframe: 12 Weeks
| Intervention | Drinks per drinking day (Mean) |
|---|---|
| Mirtazapine | 2.8 |
| Placebo | 2.0 |
Level of depressive symptoms, as indicated by the score on the Beck Depression Inventory. The Beck Depression Inventory II scoring range is as follows: 0-13 minimal depressive symptoms, 14-19 mild depressive symptoms, 20-28 moderate depressive symptoms and 29-63 severe depressive symptoms. (NCT02646449)
Timeframe: 12 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Mirtazapine | 8.0 |
| Placebo | 3.3 |
2 trials available for mianserin and Alcohol Drinking
| Article | Year |
|---|---|
The effects of mirtazapine versus placebo on alcohol consumption in male high consumers of alcohol: a randomized, controlled trial.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents, Tricyclic; Double-Blind Method; | 2015 |
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression; | 2016 |
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression; | 2016 |
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression; | 2016 |
Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Antidepressive Agents; Comorbidity; Depression; | 2016 |
3 other studies available for mianserin and Alcohol Drinking
| Article | Year |
|---|---|
An open-label pilot study of quetiapine plus mirtazapine for heavy drinkers with alcohol use disorder.
Topics: Adrenergic alpha-Antagonists; Adult; Alcohol Drinking; Alcohol-Related Disorders; Antipsychotic Agen | 2016 |
Effects of voluntary ethanol intake on the expression of Ca(2+) /calmodulin-dependent protein kinase IV and on CREB expression and phosphorylation in the rat nucleus accumbens.
Topics: Alcohol Drinking; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 4; Calcium-Calmodulin-De | 2001 |
Modulation of cellular expression of glucocorticoid receptor and glucocorticoid response element-DNA binding in rat brain during alcohol drinking and withdrawal.
Topics: Adaptation, Biological; Alcohol Drinking; Animals; Cerebral Cortex; Disease Models, Animal; DNA; Eth | 2002 |